View PDF VersionPrevious ArticleNext Article

Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence
DOI: 10.1039/C8MD90010H (Correction) Med. Chem. Commun., 2018, 9, 745-745

Correction: Chiral ruthenium polypyridyl complexes as mitochondria-targeted apoptosis inducers

Tianfeng Chen a, Wen-Jie Mei *ab, Yum-Shing Wong c, Jie Liu a, Yanan Liu a, Huang-Song Xie b and Wen-Jie Zheng *a
aDepartment of Chemistry, Jinan University, Guangzhou, 510632, China. E-mail: tzhwj@jnu.edu.cn; Fax: +86 20 8522 1263; Tel: +86 20 8522 1263
bSchool of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou, P.R. China. E-mail: wenjiemei@126.com; Fax: +86 20 8522 1263; Tel: +86 20 8522 1263
cDepartment of Biology, The Chinese University of Hong Kong, Hong Kong, SAR, China. E-mail: yumshingwong@cuhk.edu.hk; Fax: +852 2603 5745; Tel: +852 2609 6389

Received 21st February 2018 , Accepted 21st February 2018

First published on 19th March 2018

Abstract

Correction for ‘Chiral ruthenium polypyridyl complexes as mitochondria-targeted apoptosis inducers’ by Tianfeng Chen et al., Med. Chem. Commun., 2010, 1, 73–75.

The authors regret that in Table 1 of their manuscript the data for Δ-3 and Λ-3 were swapped. The corrected table is shown below.
Table 1 Cytotoxic effects of chiral Ru polypyridyl complexes on human cancer and normal cell lines
IC50/μM
Complexes A375 HepG2 SW620 PC-3 HS68 HK-2
Δ-1 35.3 ± 4.2 19.9 ± 2.5 45.2 ± 3.3 99.1 ± 7.2 — —
Λ-1 28.1 ± 3.7 11.4 ± 1.3 29.9 ± 2.0 82.7 ± 5.6 — —
Δ-2 48.4 ± 6.3 16.6 ± 2.3 36.6 ± 4.5 >200 — —
Λ-2 49.9 ± 8.5 19.9 ± 1.7 51.0 ± 3.4 >200 — —
Δ-3 17.7 ± 2.6 54.8 ± 6.4 33.2 ± 2.2 >200 — —
Λ-3 5.9 ± 1.1 10.0 ± 1.2 18.9 ± 0.9 79.5 ± 8.1 18.8 ± 3.9 108.5 ± 9.3
Cisplatin 7.3 ± 0.8 13.6 ± 2.0 30.0 ± 4.1 36.2 ± 2.9 1.8 ± 0.7 10.3 ± 2.1

In addition, on page 74, left column, top paragraph, the IC50 values for cisplatin against HS68 and HK-2 cells should be corrected to show ‘cisplatin (1.8 and 10.3 μM respectively)’ instead of ‘cisplatin (4.8 and 3.2 μM respectively)’.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

This journal is © The Royal Society of Chemistry 2018